mRESVIA RSV vaccine approved to protect patients aged 60 and over

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk of getting lower respiratory tract disease caused by RSV, compared with those who received placebo.

Follow this news feed: